Clinical Trial Update: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of CPI-818 in relapsed/refractory T-cell lymphoma is currently active but not recruiting. The trial is sponsored by Corvus Pharm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• CPI-818

Snippet

Sponsor: Corvus Pharmaceuticals, Inc. | Conditions: T-cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING